Advertisement

Annals of Hematology

, Volume 93, Issue 9, pp 1523–1529 | Cite as

Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function

  • Roberto CastelliEmail author
  • Giorgio Lambertenghi Deliliers
  • Riccardo Colombo
  • Guido Moreo
  • Paolo Gallipoli
  • Giuseppe Pantaleo
Original Article

Abstract

The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by bone marrow failure and a risk of progression to acute myeloid leukemia (AML). Anemia affects the course of disease, quality of life (QOL), and cognitive function of MDS patients. Erythroid-stimulating agents (ESAs) are effective; however, not all patients respond to ESAs. To evaluate the effectiveness of a biosimilar epoetin α (Binocrit) for the treatment of anemia in low-/intermediate-1 risk MDS patients and to evaluate the impact of ESAs on QOL and on cognitive function, 24 consecutive patients aged over 65 years were treated with Binocrit at 40,000 IU once a week for 12 weeks and were followed for at least 3 months. Responsive patients continued with 40,000 IU once a week for a further 12 weeks. Changes in QOL were assessed by the Functional Assessment of Cancer Therapy-Anemia (FACT-An), while cognitive assessment was carried out by mini-mental state examination (MMSE). All patients completed 12 weeks of therapy. Sixteen patients (66.67 %) achieved an erythroid response (ER), 15 patients (62.5 %) became transfusion independent and remained free from transfusion requirement for at least 3 months, while two patients had reduction in transfusion requirement of at least four RBC transfusions/8 weeks compared with the pretreatment transfusion requirement. Seven patients were nonresponders (29.1 %), of whom four patients were low risk and three intermediate-I risk. Seven transfusion-independent patients were low risk, and eight were intermediate-1 risk. Median hemoglobin (Hb) values were significantly higher after treatment in responders (p < 0.001). ER was maintained after 24 weeks. Statistically significant positive correlations between improvement in Hb and variations in patients’ mini-mental (Spearman’s Rho = 0.54, p < 0.01) and FACT-An scores (Spearman’s Rho = 0.59, p < 0.003) were demonstrated. This preliminary study shows that Binocrit is promising for the treatment of anemia of MDS patients. ER positively correlates with improvements in patients’ cognitive status and positive changes in QOL.

Keywords

Myelodysplastic syndromes (MDS) Anemia Erythroid-stimulating agents (ESAs) Biosimilar epoetin α (Binocrit) Quality of life (QOL) Cognitive function 

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361:1872–1885PubMedCrossRefGoogle Scholar
  2. 2.
    Castelli R, Cassin R, Cannavò A, Cugno M (2013) Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 13:1–7PubMedCrossRefGoogle Scholar
  3. 3.
    Wright RA, Pantaleo G (2013) Effort processes in achieving performance outcomes: interrelations among and roles of core constructs. Behav Brain Sci 36(6):705–706PubMedCrossRefGoogle Scholar
  4. 4.
    Pantaleo G, Miron A, Frankowski S, Ferguson M. Effects of deterrence on intensity of group identification and efforts to protect group identity. Motivation & Emotion, Special Issue on Effort, 2014, in press; ISSN: 0146–7239 EISSN: 1573–6644.Google Scholar
  5. 5.
    Lamperti E, Pantaleo G, Finocchiaro CY, Silvani A, Botturi A, Gaviani P, Sarno L, Salmaggi A (2012) Recurrent brain tumor: the impact of illness on patient’s life. Support Care Cancer 20:1327–1332PubMedCrossRefGoogle Scholar
  6. 6.
    Cazzola M, Malcovati L (2005) Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 352:536–538PubMedCrossRefGoogle Scholar
  7. 7.
    Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA (2012) Quality of life and physicians’ perception in myelodysplastic syndromes. Am J Blood Res 2:136–147PubMedCentralPubMedGoogle Scholar
  8. 8.
    Malcovati L (2007) Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 31(suppl 3):S2–S6PubMedCrossRefGoogle Scholar
  9. 9.
    Seiter K (2013) Myelodysplasia: new approaches. CurrTreat Options Oncol 14:156–169CrossRefGoogle Scholar
  10. 10.
    Fenaux P, Ades L (2013) How we treat lower-risk myelodysplastic syndromes. Blood 23(121):4280–4286CrossRefGoogle Scholar
  11. 11.
    Kelaidi C, Fenaux P (2010) Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond. Expert Opin Biol Ther 10(4):605–614PubMedCrossRefGoogle Scholar
  12. 12.
    Abraham I, Mac Donald K (2012) Clinical safety of biosimilar recombinant human erythropoietins. Expert Opin Drug Saf 11:819–840PubMedCrossRefGoogle Scholar
  13. 13.
    Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914–924PubMedCrossRefGoogle Scholar
  14. 14.
    Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373:1532–1542PubMedCrossRefGoogle Scholar
  15. 15.
    Aapro M (2009) An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology. Oncologist 14(suppl 1):1PubMedCrossRefGoogle Scholar
  16. 16.
    Castelli R, Ferrari B, Cortelezzi A, Guariglia A (2010) Thromboembolic complications in malignant haematological disorders. Curr Vasc Pharmacol 8:482–494PubMedCrossRefGoogle Scholar
  17. 17.
    Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzarà A, Pagnini D, D'Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC (2005) Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 84:167–176PubMedCrossRefGoogle Scholar
  18. 18.
    Musto P, Lanza F, Balleari E, Grossi A, Falcone A, Sanpaolo G, Bodenizza C, Scalzulli PR, La Sala A, Campioni D, Ghio R, Cascavilla N, Carella AM (2005) Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128:204–209PubMedCrossRefGoogle Scholar
  19. 19.
    Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lamberto C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury MP, Legros L, Cheze S, Testu A, Gyan E, Béné MC, Rose C, Dreyfus F, Fenaux P (2013) High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 92:633CrossRefGoogle Scholar
  20. 20.
    Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S (2013) Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? Blood 122:2286–2288PubMedCrossRefGoogle Scholar
  21. 21.
    Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A (2009) Erythropoietin or darbepoetin for patients with cancer—meta-analysis based on individual patient data. Cochrane Database Syst Rev 3, CD007303PubMedGoogle Scholar
  22. 22.
    Haag-Weber M, Vetter A, Thyroff-Friesinger U (2009) Therapeutic equivalence, long term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. ClinNephrol 72:380–e90Google Scholar
  23. 23.
    Kerkhofs L, Boschetti G, Lugini A, Stanculeanu DL, Palomo AG (2012) Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience. Future Oncol 8:751–756PubMedCrossRefGoogle Scholar
  24. 24.
    Abraham I, MacDonald K (2012) Clinical safety of biosimilar recombinant human erythropoietins. Expert Opin Drug Saf 5:819–840CrossRefGoogle Scholar
  25. 25.
    Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, van Aerts L, Vleminckx C, Wadhwa M, Schneider CK (2012) Biosimilars: what clinicians should know. Blood 120:5111–5117PubMedCrossRefGoogle Scholar
  26. 26.
    Greenberg PL, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis of myelodysplastic syndromes. Blood 89:2079–2088PubMedGoogle Scholar
  27. 27.
    Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 15(108):419–425CrossRefGoogle Scholar
  28. 28.
    Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S (2011) What are RBC-transfusion-dependence and -independence? Leuk Res 35:8–11PubMedCrossRefGoogle Scholar
  29. 29.
    Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34(3 Suppl 2):13–19PubMedGoogle Scholar
  30. 30.
    Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psych Res 12:189–198CrossRefGoogle Scholar
  31. 31.
    Balleari E, Clavio M, Arboscello E, Bellodi A, Bruzzone A, Del Corso L, Lucchetti MV, Miglino M, Passalia C, Pierri I, Ponassi I, Oneto C, Racchi O, Scudeletti M, Vignolo L, Zoppoli G, Gobbi M, Ghio R (2011) Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. Leuk Res 35:1472–1476PubMedCrossRefGoogle Scholar
  32. 32.
    Villegas A, Arrizabalaga B, Fernández-Lago C, Castro M, Mayans JR, González-Porras JR, Duarte RF, Remacha AF, Luño E, Gasquet JA (2011) Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin 27(5):951–960PubMedCrossRefGoogle Scholar
  33. 33.
    Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus F (2010) Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res 34:1430–1436PubMedCrossRefGoogle Scholar
  34. 34.
    Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, Finelli C, Locatelli F, Marchetti M, Morra E, Musto P, Visani G, Tura S (2010) Italian Society of Hematology clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 34:1576–1588PubMedCrossRefGoogle Scholar
  35. 35.
    Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, Pascutto C, Porwit A, Cazzola M, Hellström-Lindberg E (2008) Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J ClinOncol 26:3607–3613CrossRefGoogle Scholar
  36. 36.
    Geissler RG, Ganser A (1998) Myelodysplastic syndromes: a guide to treatment with epoetin and colony-stimulating factors. BioDrugs 10:97–109PubMedCrossRefGoogle Scholar
  37. 37.
    Groupe Francais des Myelodysplasies, Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L, Park S, Vaultier S, Hamza F, Beyne-rauzy MO, Cheze S, Giraudier S, Agape P, Legros L, Voillat L, Dreyfus F, Fenaux P (2006) High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133:513–519PubMedCrossRefGoogle Scholar
  38. 38.
    Musto P, Falcone A, Sanpaolo G, Bodenizza C, La Sala A, Perla G, Carella AM (2003) Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol 122:269–271PubMedCrossRefGoogle Scholar
  39. 39.
    Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus F (2010) Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res 34(11):1430–1436PubMedCrossRefGoogle Scholar
  40. 40.
    Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes, Ferrini PR, Grossi A, Vannucchi AM, Barosi G, Guarnone R, Piva N, Musto P, Balleari E (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 103:1070–1074PubMedCrossRefGoogle Scholar
  41. 41.
    Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A (1995) Apoptosis in bone marrow biopsy samples involving stromal and hemopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268–275PubMedGoogle Scholar
  42. 42.
    Greenberg PL (1998) Apoptosis and its role in myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 22:1123–1136PubMedCrossRefGoogle Scholar
  43. 43.
    Aapro M, Cornes P (2012) Diana Sun and Ivo Abraham comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol 4:95–105PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    IGES Institute. The competitive role of biosimilars in the German SHI market for pharmaceuticals. 2010Google Scholar
  45. 45.
    Hong CH, Falvey C, Harris TB, Simonsick EM, Satterfield S, Ferrucci L, Metti AL, Patel KV, Yaffe K (2013) Anemia and risk of dementia in older adults: findings from the Health ABC study. Neurology 81:528–533PubMedCrossRefGoogle Scholar
  46. 46.
    Artz AS (2008) Anemia and the frail elderly. Semin Hematol 45:261–266PubMedCrossRefGoogle Scholar
  47. 47.
    Lucca U, Tehamanti M, Mosconi P et al (2008) Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the ‘health and anemia study’. PLoS ONE 3:e1920PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Denny SD, Kuchibhatla MN, Cohen HJ (2006) Impact of anemia on mortality, cognition and function in community-dwelling elderly. Am J Med 119:327–334PubMedCrossRefGoogle Scholar
  49. 49.
    Hare GM (2004) Anaemia and the brain. Curr Opin Anaesthesiol 17:363–369PubMedCrossRefGoogle Scholar
  50. 50.
    Merelli A, Czornyj L, Lazarowski A (2013) Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy. Curr Pharm Des 19:6791–6801PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Roberto Castelli
    • 1
    Email author
  • Giorgio Lambertenghi Deliliers
    • 2
  • Riccardo Colombo
    • 1
  • Guido Moreo
    • 1
  • Paolo Gallipoli
    • 3
  • Giuseppe Pantaleo
    • 4
  1. 1.Department of Pathophysiology and TransplantationUniversity of Milan and Department of Haematology, Fondazione IRCCS Ca’ Granda-Ospedale Maggiore PoliclinicoMilanItaly
  2. 2.Fondazione MatarelliMilanItaly
  3. 3.Department of Haematology, Addenbrooke’s HospitalCambridge University Hospitals NHS TrustCambridgeUK
  4. 4.Faculty of PsychologyVita-Salute San Raffaele University of MilanMilanItaly

Personalised recommendations